Drug Approval | October 29, 2021
Boehringer Ingelheim announces EMA marketing authorisation for spesolimab
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Research collaboration covers multiple antibody research programs
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Subscribe To Our Newsletter & Stay Updated
